EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer

Piotr Stasiak, Justyna Sopel, Artur Płóciennik, Julia Maria Lipowicz, Agnieszka Anna Rawłuszko-Wieczorek, Karolina Sterzyńska, Monika Świerczewska, Jan Korbecki, Radosław Januchowski

Cells · 13.11.2026 · 15 (22) · 2075

DOI: 10.3390/cells15222075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 13.11.2026. Verfasst von Piotr Stasiak und 8 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to topotecan (TOP) limits effectiveness of chemotherapy in recurrent ovarian cancer. Increased activity of ATP-binding cassette (ABC) transporters, including breast cancer resistance protein (BCRP), is one of the mechanisms implicated in the development of TOP resistance. LDE225 (Sonidegib), a Smoothened (SMO) inhibitor targeting the Sonic Hedgehog pathway, has demonstrated antitumor properties, but its activity in TOP-resistant ovarian cancer remains insufficiently characterized. Here, we investigated LDE225 in A2780 ovarian cancer cells and their TOP-resistant, BCRP-overexpressing sublines using two-dimensional (2D) and three-dimensional (3D) models, which are relevant settings for investigating BCRP-associated TOP resistance in ovarian cancer. LDE225 reduced cell proliferation, colony formation, and migration in both TOP-sensitive and TOP-resistant cells. It also exhibited TOP-independent cytotoxicity and restored TOP sensitivity in resistant cells in both culture models. Although LDE225 did not reduce BCRP expression, fluorescence microscopy and flow cytometry demonstrated decreased transporter activity following treatment. Collectively, these findings demonstrate that LDE225 affects several phenotypic features of ovarian cancer cells and may be associated with the restoration of TOP sensitivity in resistant cells. Reduced BCRP activity may contribute to this effect, although the underlying mechanism requires further investigation. These findings support further evaluation of LDE225 as a single agent or in combination with TOP in TOP-resistant ovarian cancer.

Förderung

  • National Science Centre

Zitieren

APA

Stasiak, P., Sopel, J., Płóciennik, A., Lipowicz, J. M., Rawłuszko-Wieczorek, A. A., Sterzyńska, K., Świerczewska, M., Korbecki, J., & Januchowski, R. (2026). Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer. Cells, 15(22), 2075. https://doi.org/10.3390/cells15222075

Vancouver

Stasiak P, Sopel J, Płóciennik A, Lipowicz JM, Rawłuszko-Wieczorek AA, Sterzyńska K, et al. Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer. Cells. 2026;15(22):2075. doi:10.3390/cells15222075

BibTeX
@article{Stasiak2026,
  author = {Stasiak, Piotr and Sopel, Justyna and Płóciennik, Artur and Lipowicz, Julia Maria and Rawłuszko-Wieczorek, Agnieszka Anna and Sterzyńska, Karolina and Świerczewska, Monika and Korbecki, Jan and Januchowski, Radosław},
  title = {Shh Pathway Inhibitor LDE225 (Sonidegib) Limits BCRP Activity and Decreases Topotecan Resistance in Monolayer and Spheroid Models of Ovarian Cancer},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {2075},
  doi = {10.3390/cells15222075}
}
Kostenlos starten →